Regarding FGFR4, a previous study (Koziczak and Hynes, 2004) has shown that it is over-expressed in a significant fraction of HER2+ breast cancer samples and simultaneous inhibition of FGFR4 and ERBB2 using small molecule inhibitors have synergistic anti-proliferative effect. The gene discussed is ERBB2; the disease is breast carcinoma.